Definition and new approaches to understanding the pathogenesis of Drave syndrome in children ; Определение и новые подходы к пониманию патогенеза синдрома Драве у детей

Συγγραφείς: A. N. Ulyakov, M. Yu. Bobylova, V. S. Lobanova, К. Yu. Мukhin, O. A. Pylaeva, I. S. Tishchenko, S. O. Kazakov, А. Н. Уляков, М. Ю. Бобылова, В. С. Лобанова, К. Ю. Мухин, О. А. Пылаева, И. С. Тищенко, С. О. Казаков

Πηγή: Russian Journal of Child Neurology; Том 20, № 1 (2025); 17-24 ; Русский журнал детской неврологии; Том 20, № 1 (2025); 17-24 ; 2412-9178 ; 2073-8803

Θεματικοί όροι: фармакорезистентность, SCN1A, voltage-sensitive sodium channels, epilepsy, anticonvulsants, drug resistance, потенциал-чувствительные натриевые каналы, эпилепсия, противосудорожные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://rjdn.abvpress.ru/jour/article/view/508/346; Мухин К.Ю., Глухова Л.Ю., Бобылова М.Ю. и др. Эпилептические синдромы. Диагностика и терапия. Руководство для врачей. 5-е изд-е. М.: Издательство «БИНОМ», 2020. 672 с.; Ahern C.A., Payandeh J., Bosmans F., Chanda B. The hitchhiker’s guide to the voltage-gated sodium channel galaxy. J Gen Physiol 2016;147:1–24. DOI:10.1085/jgp.201511492; Biella G., Di Febo F., Goffredo D. et al. Differentiating embryonic stem derived neural stem cells show a maturation-dependent pattern of voltage-gated sodium current expression and graded action potentials. Neuroscience 2007;149:38–52. DOI:10.1016/j.neuroscience.2007.07.021; Brunklaus A., Ellis R., Reavey E. et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012;135:2329–36. DOI:10.1093/brain/aws151; Brunklaus A., Zuberi S.M. Dravet syndrome – from epileptic encephalopathy to channelopathy. Epilepsia 2014;55(7):979–84. DOI:10.1111/epi.12652; Catterall W.A. Voltage-gated sodium channels at 60: structure, function and pathophysiology. J Physiol 2012;590:2577–89. DOI:10.1113/jphysiol.2011.224204; Catterall W.A., Goldin A.L., Waxman S.G. International Union of Pharmacology. XLVII. Nomenclature and structure-function re- lationships of voltage-gated sodium channels. Pharmacol Rev 2005;57:397–409. DOI:10.1124/pr.57.4.4; Catterall W.A., Zheng N. Deciphering voltage-gated Na+ and Ca2+ channels by studying prokaryotic ancestors. Trends Biochem Sci 2015;40:526–34. DOI:10.1016/j.tibs.2015.07.002; Cetica V., Chiari S., Mei D. et al. Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations. Neurology 2017;88:1037–44. DOI:10.1212/WNL.0000000000003716; Ceulemans B., Cras P. Severe myoclonic epilepsy in infancy. Relevance for the clinician of severe epilepsy starting in infancy. Acta Neurol Belg 2004;104(3):95–9.; Cheah C.S., Westenbroek R.E., Roden W.H. et al. Correlations in timing of sodium channel expression, epilepsy, and sudden death in Dravet syndrome. Channels 2013;7:468–72. DOI:10.4161/chan.26023; Claes L., Del-Favero J., Ceulemans B. et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68(6):1327–32. DOI:10.1086/320609; Dravet C. Severe myoclonic epilepsy in infants and its related syndromes. Epilepsia 2000;41(Suppl 9):7. DOI:10.1111/j.1528-1157.2000.tb02210.x; Dravet C., Bureau M., Oguni H. Dravet Syndrome (Severe Myoclonic Epilepsy in Infancy). Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey Eurotext, 2012. Pp. 125–156.; Dravet C., Bureau M., Oguni H. et al. Severe myoclonic epilepsy in infancy (Dravet Syndrome). In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 4th edn. London: John Libbey Eurotext Ltd, 2005. Pp. 89–113.; Gamal El-Din T.M., Lenaeus M.J., Catterall W.A. Structural and functional analysis of sodium channels viewed from an evolutionary perspective. Handb Exp Pharmacol 2018;246:53–72. DOI:10.1007/164_2017_61; Human SCN1A Gene. Available at: http://www.gzneurosci.com/scn1adatabase/expression.php.; Isom L.L., Ragsdale D.S., De Jongh K.S. et al. Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 1995;83:433–42. DOI:10.1016/0092-8674(95)90121-3; Meng H., Xu H.Q., Yu L. et al. The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 2015;36(6):573–80. DOI:10.1002/humu.22782; Mouhi H.E., Abbassi M., Jalte M. et al. The genetic facets of Dravet syndrome: Recent INsights. Ann Child Neurol 2024;32(2):67–82.; Nabbout R., Desguerre I., Sabbagh S. et al. An unexpected EEG course in Dravet syndrome. Epilepsy Res 2008;81:90–5. DOI:10.1016/j.eplepsyres.2008.04.015; Ogiwara I., Miyamoto H., Morita N. et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: A circuit basis for epileptic seizures in mice carrying an SCN1A gene mutation. J Neurosci 2007;27:5903–14. DOI:10.1523/JNEUROSCI.5270-06.2007; Qu Y., Isom L.L., Westenbroek R.E. et al. Modulation of cardiac Na+ channel expression in Xenopus oocytes by beta 1 subunits. J Biol Chem 1995;270:25696–701. DOI:10.1074/jbc.270.43.25696; SCN1A Variants Database. Available at: https://www.youtube.com/watch?v=h7wHS7IOT4M.; Stafstrom C.E. Severe epilepsy syndromes of early childhood: The link between genetics and pathophysiology with a focus on SCN1A mutations. J Child Neurol 2009;24:15–23. DOI:10.1177/0883073809338152; Wirrell E.C., Hood V., Knupp K.G. et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia 2022;63(7):1761–77. DOI:10.1111/epi.17274; Wu Y.W., Sullivan J., McDaniel S.S. et al. Incidence of Dravet syndrome in a US population. Pediatrics 2015;136:e1310–5. DOI:10.1542/peds.2015-1807; Yu F.H., Catterall W.A. Overview of the voltage-gated sodium channel family. Genome Biol 2003;4(3):207. DOI:10.1186/gb-2003-4-3-207; Yu F.H., Mantegazza M., Westenbroek R.E. et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 2006;9:1142–9. DOI:10.1038/nn1754; https://rjdn.abvpress.ru/jour/article/view/508

Διαθεσιμότητα: https://rjdn.abvpress.ru/jour/article/view/508
https://doi.org/10.17650/2073-8803-2025-20-1-17-24

Epilepsy and pregnancy ; Эпилепсия и беременность

Συγγραφείς: P. N. Vlasov, A. M. Azhigova, E. B. Efimkova, V. A. Petrukhin, П. Н. Власов, А. М. Ажигова, Е. Б. Ефимкова, В. A. Петрухин

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 3 (2024); 4-11 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 3 (2024); 4-11 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-3

Θεματικοί όροι: крупные врожденные пороки развития, pregnancy, pregnancy planning, pregnancy management, anticonvulsants, postpartum period, teratogenesis, major congenital malformations, беременность, подготовка к беременности, ведение беременности, противосудорожные препараты, послеродовой период, тератогенез

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2271/1658; https://nnp.ima-press.net/nnp/article/view/2271/1716; Tomson T, Battino D, Bromley R, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019 Dec 1;21(6):497-517. doi:10.1684/epd.2019.1105; Watila MM, Beida O, Kwari S, et al. Seizure occurrence, pregnancy outcome among women with active convulsive epilepsy: one year prospective study. Seizure. 2015 Mar;26:7-11. doi:10.1016/j.seizure.2015.01.007. Epub 2015 Jan 14.; De Lima Leite M, Toporcov TN, Pai JD, da Silva JC. Socio-demographic profiles and obstetrics outcomes of pregnant women with epilepsy in a vulnerability State, Brazil. PLoS One. 2022 Jul 20;17(7):e0271328. doi:10.1371/journal.pone.0271328; Карлов ВА, Власов ПН, Петрухин ВА идр. Глава 32.3 «Эпилепсия и беременность». В кн.: Карлов ВА. Эпилепсия у детей и взрослых, женщин и мужчин. Руководство для врачей. 2-е изд. Москва: Издательский дом «БИНОМ»; 2019. С. 672-91.; Harden CL, Hopp J, Ting TY, et al; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy — Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009 May;50(5):1229-36. doi:10.1111/j.1528-1167.2009.02128.x; Pennell PB, French JA, May RC, et al; MONEAD Study Group. Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy. N Engl J Med. 2020 Dec 24;383(26):2547-56. doi:10.1056/NEJMoa2008663; Battino D, Tomson T, Bonizzoni E, et al; EURAP Study Group. Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia. 2013 Sep;54(9):1621-7. doi:10.1111/epi.12302. Epub 2013 Jul 12.; Voinescu PE, Ehlert AN, Bay CP, et al. Variations in Seizure Frequency During Pregnancy and Postpartum by Epilepsy Type. Neurology. 2022 Feb 22;98(8):e802-e807. doi:10.1212/WNL.0000000000013056. Epub 2021 Dec 10.; Eadie MJ. Pregnancy and the Control of Epileptic Seizures: A Review. Neurol Ther. 2021 Dec;10(2):455-68. doi:10.1007/s40120-021-00252-5. Epub 2021 May 14.; Reisinger TL, Newman M, Loring DW, et al. Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy. Epilepsy Behav. 2013 Oct;29(1):13-8. doi:10.1016/j.yebeh.2013.06.026. Epub 2013 Aug 2.; Cagnetti C, Lattanzi S, Foschi N, et al. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014 Jul 22;83(4):339-44. doi:10.1212/WNL.0000000000000619. Epub 2014 Jun 18.; La Neve A, Boero G, Francavilla T, et al. Prospective, case-control study on the effect of pregnancy on seizure frequency in women with epilepsy. Neurol Sci. 2015 Jan;36(1):79-83. doi:10.1007/s10072-014-1908-0. Epub 2014 Jul 29.; Shahla M, Hijran B, Sharif M. The course of epilepsy and seizure control in pregnant women. Acta Neurol Belg. 2018 Sep;118(3):459-64. doi:10.1007/s13760-018-0974-0. Epub 2018 Jul 6.; Vajda FJ, O'Brien TJ, Lander CM, et al. Does pregnancy per se make epilepsy worse? Acta Neurol Scand. 2016 May;133(5):380-3. doi:10.1111/ane.12479. Epub 2015 Sep 8.; Edey S, Moran N, Nashef L. SUDEP and epilepsy-related mortality in pregnancy. Epilepsia. 2014 Jul;55(7):e72-4. doi:10.1111/epi.12621. Epub 2014 Apr 22.; Sahoo S, Klein P. Maternal complex partial seizure associated with fetal distress. Arch Neurol. 2005 Aug;62(8):1304-5. doi:10.1001/archneur.62.8.1304; Chen YH, Chiou HY, Lin HC, Lin HL. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol. 2009 Aug;66(8):979-84. doi:10.1001/archneurol.2009.142; Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013 Mar;12(3):244-52. doi:10.1016/S1474-4422(12)70323-X. Epub 2013 Jan 23.; Baker GA, Bromley RL, Briggs M, et al; Liverpool and Manchester Neurodevelopment Group. IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015 Jan 27;84(4):382-90. doi:10.1212/WNL.0000000000001182. Epub 2014 Dec 24.; Harden CL, Pennell PB, Koppel BS, et al; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009 May;50(5):1247-55. doi:10.1111/j.1528-1167.2009.02130.x; Voinescu PE, Park S, Chen LQ, et al. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018 Sep 25;91(13):e1228-e1236. doi:10.1212/WNL.0000000000006240. Epub 2018 Sep 5.; Дмитренко ДВ, Шнайдер НА, Горошкин АН и др. Российский регистр беременности и эпилепсии. Неврология, нейропсихиатрия, психосоматика. 2017;9(1S):21-5. doi:10.14412/2074-2711-2017-1S-21-25.; Blotiere PO, Raguideau F, Weill A, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology. 2019 Jul 9;93(2):e167-e180. doi:10.1212/WNL.0000000000007696. Epub 2019 Jun 12.; Tomson T, Battino D, Bonizzoni E, et al; EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018 Jun;17(6):530-8. doi:10.1016/S1474-4422(18)30107-8. Epub 2018 Apr 18.; Hernandez-Diaz S, Smith CR, Shen A, et al; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012 May 22;78(21):1692-9. doi:10.1212/WNL.0b013e3182574f39. Epub 2012 May 2.; Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):1029-34. doi:10.1136/jnnp-2013-306318. Epub 2014 Jan 20.; Vajda FJ, O'Brien TJ, Lander CM, et al. The teratogenicity of the newer antiepileptic drugs — an update. Acta Neurol Scand. 2014 Oct;130(4):234-8. doi:10.1111/ane.12280. Epub 2014 Jul 18.; Huber-Mollema Y, Oort FJ, Lindhout D, Rodenburg R. Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy. Epilepsia. 2019 Jun;60(6):1069-82. doi:10.1111/epi.15968; Veiby G, Daltveit AK, Schjolberg S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective populationbased study. Epilepsia. 2013 Aug;54(8):1462-72. doi:10.1111/epi.12226. Epub 2013 Jul 19.; Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011 Feb;134(Pt 2):396-404. doi:10.1093/brain/awq352. Epub 2011 Jan 11.; Bromley RL, Calderbank R, Cheyne CP, et al; UK Epilepsy and Pregnancy Register. Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. Neurology. 2016 Nov 1;87(18):1943-53. doi:10.1212/WNL.0000000000003157. Epub 2016 Aug 31.; Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014 Oct 30;2014(10):CD010236. doi:10.1002/14651858.CD010236.pub2; Meador KJ, Baker GA, Browning N, et al; Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014 Aug;168(8):729-36. doi:10.1001/jamapediatrics.2014.118; Elkaer LS, Bech BH, Sun Y, et al. Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children. JAMA Neurol. 2018 Jun 1;75(6):663-71. doi:10.1001/jamaneurol.2017.5035; Авакян ГН, Блинов ДВ, Авакян ГГ идр. Ограничения использования вальпроевой кислоты у девочек и женщин: расширение противопоказаний в инструкции по медицинскому применению, основанное на данных реальной клинической практики. Эпилепсия и пароксизмальные состояния. 2019;11(2):110-23.; Czeizel AE, Dudas I, Vereczkey A, Banhidy F. Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. Nutrients. 2013 Nov 21;5(11):4760-75. doi:10.3390/nu5114760; Bjork M, Riedel B, Spigset O, et al. Association of Folic Acid Supplementation During Pregnancy With the Risk of Autistic Traits in Children Exposed to Antiepileptic Drugs In Utero. JAMA Neurol. 2018 Feb 1;75(2):160-8. doi:10.1001/jamaneurol.2017.3897. Erratum in: JAMA Neurol. 2018 Apr 1;75(4):518.; Husebye ESN, Gilhus NE, Riedel B, et al. Verbal abilities in children of mothers with epilepsy: Association to maternal folate status. Neurology. 2018 Aug 28;91(9):e811-e821. doi:10.1212/WNL.0000000000006073. Epub 2018 Aug 1.; Власов ПН. Глава 5. Эпилепсия. В кн.: Власов ПН, редактор. Неврологическая патология и беременность. Москва: МЕДпресс-информ; 2022. С. 92-102.; Власов ПН, Петрухин ВА, Ахвледиани КН, Лубнин АЮ. Неврологическая патология и беременность. 2-е изд. Москва: МЕДпресс-информ; 2023. 216 с.; Reimers A, Helde G, Brathen G, Brodtkorb E. Lamotrigine and its N2-glu-curonide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Res. 2011 May;94(3):198-205. doi:10.1016/j.eplep-syres.2011.02.002. Epub 2011 Feb 26.; Karanam A, Pennell PB, French JA, et al. Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age. Ann Neurol. 2018 Oct;84(4):556-63. doi:10.1002/ana.25321. Epub 2018 Oct 11.; Министерство здравоохранения Российской Федерации. Клинические рекомендации «Эпилепсия и эпилептический статус у взрослых и детей». Москва; 2022. 277 с.; Minicucci F, Ferlisi M, Brigo F, et al. Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy. Epilepsy Behav. 2020 Jan;102:106675. doi:10.1016/j.yebeh.2019.106675. Epub 2019 Nov 22.; Vlasov PN, Drojina GR, Petrukchin VA, et al. Haemostatic parameters of newborns from mothers with epilepsy. Epileptologia. 2012;20(1):5-9.; Tomson T, Battino D, Bromley R, et al. Executive Summary: Management of epilepsy in pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epilepsia. 2019 Dec;60(12):2343-5. doi:10.1111/epi.16395. Epub 2019 Nov 24.; Tomson T, Battino D, Bromley R, et al. Global Survey of Guidelines for the Management of Epilepsy in Pregnancy: A report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epilepsia Open. 2020 Aug 5;5(3):366-70. doi:10.1002/epi4.12420

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2271
https://doi.org/10.14412/2074-2711-2024-3-4-11

Genetic determinism of epilepsy refractoriness in patients with congenital cerebral p ; Генетическая детерминированность рефрактерности течения эпилепсии у детей с врожденными церебральными параличами

Συγγραφείς: P. L. Sokolov, N. V. Chebanenko, D. M. Mednaya, П. Л. Соколов, Н. В. Чебаненко, Д. М. Медная

Πηγή: Russian Journal of Child Neurology; Том 18, № 2-3 (2023); 22-30 ; Русский журнал детской неврологии; Том 18, № 2-3 (2023); 22-30 ; 2412-9178 ; 2073-8803

Θεματικοί όροι: противосудорожные препараты, cerebral palsy, epilepsy, genetics, pharmacogenetics, antiepileptic drugs, anticonvulsants, церебральный паралич, эпилепсия, генетика, фармакогенетика, противоэпилептические препараты

Περιγραφή αρχείου: application/pdf

Relation: https://rjdn.abvpress.ru/jour/article/view/443/300; Брюханова Н.О., Жилина С.С., Беленикин М.С. и др. Возможности генетического тестирования при резистентных формах эпилепсии. Педиатрия 2015;94(5):77–80. @@Bryukhanova N.O., Zhilina S.S., Belenikin M.S. et al. Possibilities of genetic testing in resistant forms of epilepsy. Pediatriya = Pediatrics 2015;94(5):77–80. (In Russ.); Заваденко Н.Н., Холин А.А. Эпилепсия у детей с митохондриальными заболеваниями: особенности диагностики и лечения. Эпилепсия и пароксизмальные состояния 2012;4(2):21–7. @@Zavadenko N.N., Choline A.A. Epilepsy in children with mitochondrial diseases: features of diagnosis and treatment. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and paroxysmal conditions 2012;4(2):21–7. (In Russ.); Кожанова Т.В., Жилина С.С., Мещерякова Т.И. и др. Значение секвенирования экзома для диагностики эпилепсии у детей. Эпилепсия и пароксизмальные состояния 2019;11(4):379–87. DOI:10.17749/2077-8333.2019.11.4.379-387 @@Kozhanova T.V., Zhilina S.S., Meshcheryakova T.I. et al. The value of exome sequencing for the diagnosis of epilepsy in children. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and paroxysmal conditions 2019;11(4):379–87. (In Russ.). DOI:10.17749/2077-8333.2019.11.4.379-387; Миронов М.Б., Чебаненко Н.В., Быченко В.Г. и др. Коморбидность детского церебрального паралича и доброкачественных эпилептиформных паттернов детства на ЭЭГ на примере клинических случаев дизиготных близнецов. Эпилепсия и пароксизмальные состояния 2018;10(3):52–62. DOI:10.17749/2077-8333.2018.10.3.052-062 @@Mironov M.B., Chebanenko N.V., Bychenko V.G. et al. Comorbidity of infantile cerebral palsy and benign epileptiform patterns of childhood on EEG on the example of clinical cases of dizygotic twins. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and paroxysmal conditions 2018;10(3):52–62. (In Russ.). DOI:10.17749/2077-8333.2018.10.3.052-062; Мухин К.Ю., Кузьмич Г.В., Миронов М.Б. Эпилепсия при церебральных параличах у детей: электроклинические особенности и прогноз. Вестник РГМУ 2011;5:37.@@Mukhin K.Yu., Kuzmich G.V., Mironov M.B. Epilepsy in children with cerebral palsy: electroclinical features and prognosis. Vestnik RGMU = Bulletin of the Russian State Medical University 2011;5:37. (In Russ.); Пак Л.А., Кузенкова Л.М., Фисенко А.П. и др. Генетически детерминированные болезни у детей в структуре детского церебрального паралича. Российский педиатрический журнал 2018;21(6):324–30. @@Pak L.A., Kuzenkova L.M., Fisenko A.P. et al. Genetically determined diseases in children in the structure of infantile cerebral palsy. Rossijskiy pediatricheskiy zhurnal = Russian Pediatric Journal 2018;21(6):324–30. (In Russ.); Соколов П.Л., Чебаненко Н.В., Зыков В.П. и др. Врожденные церебральные параличи: генетическая природа и нозологическая целостность. Русский журнал детской неврологии 2020;15(3–4): 65–77. DOI:10.17650/2073-8803-2020-15-3-4-65-77 @@Sokolov P.L., Chebanenko N.V., Zykov V.P. et al. Congenital cerebral palsy: genetic nature and nosological integrity. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2020;15(3– 4):65–77. (In Russ.). DOI:10.17650/2073-8803-2020-15-3-4-65-77; Холин А.А., Заваденко Н.Н., Есипова Е.С. Детский церебральный паралич и эпилепсия. Вопросы практической педиатрии 2016;11(4):66–72. DOI:10.20953/1817-7646-2016-4-66-72 @@Kholin A.A., Zavadenko N.N., Esipova E.C. Cerebral palsy and epilepsy. Voprosy prakticheskoy pediatrii = Practical issues of pediatrics 2016;11(4):66–72. (In Russ.) DOI:10.20953/1817-7646-2016-4-66-72; Bahi-Buisson N., Poirier K., Boddaert N. et al. Refinement of cortical dysgeneses spectrum associated with TUBA1A mutations. J Med Genet 2008;45:647–53.; Banerjee A., Vikas B., Gunjan D. et al. ADSL deficiency – the lesser–known metabolic epilepsy in infancy. Indian J Pediatr 2021;88(3):263–5. DOI:10.1007/s12098-020-03435-4 11. Fahey M.C., Maclennan A.H., Kretzschmar D. et al. The genetic basis of cerebral palsy. Dev Med Child Neurol 2017;59(5):462–9. DOI:10.1111/dmcn.13363; Fallet-Bianco C., Loeuillet L., Poirier K. et al. Neuropathological phenotype of a distinct form of lissencephaly associated with mutations in TUBA1A. Brain 2008;131:2304–20.; Goto A., Ishii A., Shibata M. et al. Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy. Epilepsia 2019;60(9):1870–80. DOI:10.1111/epi.16314; Keays D.A., Tian G., Poirier K. et al. Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans. Cell 2007;128:45–57.; Kolc K., Møller R., Sadleir L. et al. PCDH19 pathogenic variants in males: expanding the phenotypic spectrum. Adv Exp Med Biol 2020;1298:177–87. DOI10.1007/5584_2020_574; Kumar R.A., Pilz D.T., Babatz T.D. et al. TUBA1A mutations cause wide spectrum lissencephaly (smooth brain) and suggest that multiple neuronal migration pathways converge on alpha tubulins. Hum Mol Genet 2010;19:2817–27.; McMichael G., Bainbridge M.N., Haan E. et al. Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy. Mol Psychiatry 2015;20(2):176–82. DOI:10.1038/mp.2014.189; Mitta N., Menon R., McTague A. et al. Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: A single centre experience. Epilepsy Res 2020;166:106398. DOI:10.1016/j.eplepsyres.2020.106398; Parsamanesh N., Safarpour H., Etesam S. et al. Identification and in silico characterization of a novel point mutation within the phosphatidylinositol glycan anchor biosynthesis class G gene in an Iranian family with intellectual disability. J Mol Neurosci 2019;69(4):538–45. DOI:10.1007/s12031-019-01376-у; Patino G.A., Claes L.R., Lopez-Santiago L.F. et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 2009;29(34):10764–78. DOI:10.1523/JNEUROSCI.2475-09.2009; Surveillance of Cerebral Palsy in Europe. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42:816–24.; Zhang S., Zhang Z., Shen Y. et al. SCN9A epileptic encephalopathy mutations display a gain-of-function phenotype and distinct sensitivity to oxcarbazepine. J Neurosci Bull 2020;36(1):11–24. DOI:10.1007/s12264-019-00413-5; https://rjdn.abvpress.ru/jour/article/view/443

Διαθεσιμότητα: https://rjdn.abvpress.ru/jour/article/view/443
https://doi.org/10.17650/2073-8803-2023-18-2-3-22-30

Drug-Induced Eosinophilia ; Лекарственно-индуцированная эозинофилия

Συγγραφείς: O. D. Ostroumova, E. Yu. Shahova, A. I. Kochetkov, О. Д. Остроумова, Е. Ю. Шахова, А. И. Кочетков

Συνεισφορές: The study was performed without external funding., Работа выполнена без спонсорской поддержки.

Πηγή: Safety and Risk of Pharmacotherapy; Том 7, № 4 (2019); 176-189 ; Безопасность и риск фармакотерапии; Том 7, № 4 (2019); 176-189 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2019-7-4

Θεματικοί όροι: нестероидные противовоспалительные препараты, drug-induced eosinophilia, аdverse drug reaction, antibiotics, sulfanilamides, antimalarial drugs, anti-seizure medications, nonsteroidal anti-inflammatory drugs, лекарственно-индуцированная эозинофилия, нежелательные побочные реакции, антибиотики, сульфаниламиды, противомалярийные препараты, противосудорожные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/156/203; Berkow R, Fletcher AJ, eds. The Merck manual of diagnosis and therapy. 16th ed. Rahway: Merck Research Laboratories; 1992.; Weatherall DJ, Ledingham JGG, Warrell DA, eds. Oxford textbook of medicine. 3rd ed. Oxford: Oxford University Press; 1995.; Maidment I, Williams C. Drug-induced eosinophilia. Pharm J. 2000;264(7078):71–6.; Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301–8. https://doi.org/10.1016/j.alit.2019.03.006; Watanabe H. Recent advances in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Immunol Res. 2018;2018:5163129. https://doi.org/10.1155/2018/5163129; Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012;49(2):149–59. https://doi.org/10.1053/j.seminhematol.2012.01.006; Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP, Nelson SB. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. J Allergy Clin Immunol. 2015;136(5):1288–94.e1. https://doi.org/10.1016/j.jaci.2015.04.005; Rauscher C, Freeman A. Drug-induced eosinophilia. Allergy Asthma Proc. 2018;39(3):252–6. https://doi.org/10.2500/aap.2018.39.4120; Lopez M, Salvaggio JE. Eosinophilic pneumonias. Immunol Allergy Clin North Am. 1992;12(2):349–63.; Jessop JD, Dippy J, Turnbull A, Bright M. Eosinophilia during gold therapy. Rheumatology. 1974;13(2):75–80. https://doi.org/10.1093/rheumatology/13.2.75; Edelman J, Davis P, Owen ET. Prevalence of eosinophilia during gold therapy for rheumatoid arthritis. J Rheumatol. 1983;10(1):121–3.; Савочкина ДИ. DRESS-синдром (DIHS-синдром): этиология, патогенез, симптомы. Международный студенческий научный вестник. 2018;(4):298–300.; Воржева ИИ, Черняк БА. Поражения легких при системной реакции лекарственной гиперчувствительности с эозинофилией: обзор литературы и клинические наблюдения. Практическая пульмонология. 2018;(2):59–68.; Moshari J, Niazkar HR, Shahri MK, Ghorbani M, Darafshi R. Drug-induced eosinophilia secondary to the cotrimoxazole administration in acute brucellosis. Asian J Pharm Clin Res. 2018;11(9):3–4. http://dx.doi.org/10.22159/ajpcr.2018.v11i9.25610; Morrisroe K, Wong M. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis. Rheumatology. 2015;54(11):2113–4. https://doi.org/10.1093/rheumatology/kev275; Broccolo F, Ciccarese G, Picciotto A, Drago F. A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection. J Hepatol. 2015;62(1):248–9. https://doi.org/10.1016/j.jhep.2014.09.014; Демко ИВ, Собко EA, Ищенко ОП, Соловьева ИА, Крапошина АЮ, Аристархова ЛВ и др. DIHS/DRESS синдром, вызванный карбамазепином. Лечение и профилактика. 2016;3(19):56–9.; Шаленкова МА, Михайлова ЗД. Эозинофилия как осложнение длительного приема кордарона. Медицинский альманах. 2009;(1):215–8.; Kowalszki A, Sheikh J, Weller PF. Eosinophils and eosinophilia. In: Rich RR, ed. Clinical immunology: principles and practice. 4th ed. London: Elsevier Saunders; 2013. P. 298–309.; Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139(8):683–93. https://doi.org/10.7326/0003-4819-139-8-200310210-00012; Wykoff R. Eosinophilia. Southern Med J. 1986;79(5):608–12. https://doi.org/10.1097/00007611-198605000-00021; Spry CJF. Eosinophilia and allergic reactions to drugs. Clin Haematol. 1980;9(3):521–34.; Girard JP, Kunz ML, Kobayashi S, Rose NR, Arbesman CE. Penicillin hypersensitivity with eosinophilia: a case report with immunologic studies. Am J Med. 1967;42(3):441–8. https://doi.org/10.1016/0002-9343(67)90272-0; Romano A, Di Fonso M, Pocobelli D, Giannarini L, Venuti A, Garcovich A. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. J Investig Allergol Clin Immunol. 1993;3(1):53–5.; Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug related myocarditis: I. Hypersensitivity myocarditis. Hum Pathol. 1981;12(10):900–7. https://doi.org/10.1016/s0046-8177(81)80195-5; Felman RH, Sutherland DB, Conklin JL, Mitros FA. Eosinophilic cholecystitis, appendiceal inflammation, pericarditis, and cephalosporin-associated eosinophilia. Dig Dis Sci. 1994;39(2):418–22. https://doi.org/10.1007/bf02090217; Verma S, Kieff E. Cephalexin-related nephropathy. JAMA. 1975;234(6):618–9. https://doi.org/10.1001/jama.1975.03260190046023; Smith JH, Weinstein VF. Cephalexin associated pulmonary infiltration with circulating eosinophilia. Br Med J (Clin Res Ed). 1987;294(6574):776. https://doi.org/10.1136/bmj.294.6574.776-d; Marik PE, Ferris N. Delayed hypersensitivity reaction to vancomycin. Pharmacotherapy. 1997;17(6):1341–4.; Hannah B, Kimmel P, Dosa S, Turner M. Vancomycin-induced toxic epidermal necrolysis. South Med J. 1990;83(6):720–2. https://doi.org/10.1097/00007611-199006000-00035; Frye RF, Job ML, Dretler RH, Rosenbaum BJ. Teicoplanin nephrotoxicity: first case report. Pharmacotherapy. 1992;12(3):240–2.; Shaughnessy KK, Bouchard SM, Mohr MR, Herre JM, Salkey KS. Minocycline-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with persistent myocarditis. J Am Acad Dermatol. 2010;62(2):315–8. https://doi.org/10.1016/j.jaad.2009.05.046; Sitbon O, Bidel N, Dussopt C, Azarian R, Braud ML, Lebargy F, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med. 1994;154(14):1633–40. https://doi.org/10.1001/archinte.1994.00420140105013; Parneix-Spake A, Bastuji-Garin S, Lobut JB, Erner J, Guyet-Rousset P, Revuz J, Roujeau JC. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol. 1995;131(4):490–1. https://doi.org/10.1001/archderm.1995.01690160120024; Maubec E, Wolkenstein P, Loriot MA, Wechsler J, Mulot C, Beaune P, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology. 2008;216(3):200–4. https://doi.org/10.1159/000112926; Ho D, Tashkin DP, Bein ME, Sharma O. Pulmonary infiltrates with eosinophilia associated with tetracycline. Chest. 1979;76(1):33–6. https://doi.org/10.1378/chest.76.1.33; Lorber B, Cutler C, Barry WE. Allergic rash due to amphotericin B. Ann Intern Med. 1976;84(1):54. https://doi.org/10.7326/0003-4819-84-1-54; Asperilla MO, Smego RA Jr. Eosinophilic meningitis associated with ciprofloxacin. Am J Med. 1989;87(5):589–90. https://doi.org/10.1016/S0002-9343(89)80620-5; Feinmann L. Drug-induced lung disease: pulmonary eosinophilia and sulphonamides. Proc R Soc Med. 1975;68(7):440–1.; Sovijärvi ARA, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoin induced acute, subacute and chronic pulmonary reactions. A report of 66 cases. Scand J Resp Dis. 1977;58(1):41–50.; Davidson AC, Bateman C, Shovlin C, Marrinan M, Burton GH, Cameron IR. Pulmonary toxicity of malaria prophylaxis. BMJ. 1989;297(6658):1240–1. https://doi.org/10.1136/bmj.297.6658.1240; Janier M, Guillevin L, Badillet G. Pulmonary eosinophilia associated with dapsone. Lancet. 1994;343(8901):860–1. https://doi.org/10.1016/S0140-6736(94)92066-4; Wong PC, Yew WW, Wong CF, Choi HY. Ethambutol-induced pulmonary infiltrates with eosinophilia and skin involvement. Eur Respir J. 1995;8(5):866–8.; Lee M, Berger HW. Eosinophilia caused by rifampin. Chest. 1980;77(4):579. https://doi.org/10.1378/chest.77.4.579b; Lange P, Oun H, Fuller S, Turney JH. Eosinophilic colitis due to rifampicin. Lancet. 1994;344(8932):1296–7.https://doi.org/10.1016/S0140-6736(94)90782-X; Zhang SN, He QX, Yang NB, Ni SL, Lu MQ. Isoniazid-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Presenting as acute eosinophilic myocarditis. Intern Med. 2015;54(10):1227–30. https://doi.org/10.2169/internalmedicine.54.3511.; Kayanakis JG, Giraud P, Fauvel JM, Bounhoure JP. Eosinophilia during captopril treatment. Lancet. 1980;316(8200):923. https://doi.org/10.1016/S0140-6736(80)92085-1; Watanabe K, Nishimura K, Shiode M, Sekiya M, Ikeda S, Inoue Y, Iwanaga C. Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia. Intern Med. 1996;35(2):142–5. https://doi.org/10.2169/internalmedicine.35.142; Barnes JN, Davies ES, Gent CB. Rash, eosinophilia and hyperkalaemia associated with enalapril. Lancet. 1983;322(8340):41–2. https://doi.org/10.1016/S0140-6736(83)90020-X; Benard A, Melloni B, Gosselin B, Bonnaud F, Wallaert B. Perindopril-associated pneumonitis. Eur Respir J. 1996;9(6):1314–6. https://doi.org/10.1183/09031936.96.09061314; Wathen CG, MacDonald T, Wise LA, Boyd SM. Eosinophilia associated with spironolactone. Lancet. 1986;1(8486):919–20. https://doi.org/10.1016/s0140-6736(86)91026-3; Dominguez EA, Hamill RJ. Drug-induced fever due to diltiazem. Arch Intern Med. 1991;151(9):1869–70. https://doi.org/10.1001/archinte.1991.00400090141026; Dukes MNG. Meylers side effects of drugs. 13th ed. Oxford: Elsevier Press; 1996.; Marcos Sánchez F, Aparicio Martínez JC, Durán Pérez-Navarro A. Eosinophilia caused by low-molecular-weight heparin. An Med Interna. 1992;9(5):256.; Taliercio CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc. 1985;60(7):463–8. https://doi.org/10.1016/S0025-6196(12)60870-2; Bacon HM. Eosinophilia associated with chlorpromazine therapy. Am J Psychiatry. 1964;120(9):915–6. https://doi.org/10.1176/ajp.120.9.915; Shear MK. Chlorpromazine-induced PIE syndrome. Am J Psychiatry. 1978;135(4):492–3. https://doi.org/10.1176/ajp.135.4.492; Keshaven MS, Kennedy JS, eds. Adverse hematological effects in drug-induced dysfunction in psychiatry. New York: Hemisphere Publishing Corporation; 1992.; Amsterdam JD. Loeffler’s syndrome: an uncommon adverse reaction to imipramine. Int Clin Psychopharmacol. 1986;1(3):260–2.; Salerno SM, Strong JS, Roth BJ, Sakata V. Eosinophilic pneumonia and respiratory failure associated with a trazodone overdose. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2170–2. https://doi.org/10.1164/ajrccm.152.6.8520792; Anderson BN, Henrikson IR. Jaundice and eosinophilia associated with amitriptyline. J Clin Psychiatry. 1978;39(9):730–1.; Hartzema AG, Porta MS, Tilson HH, Milburn DS, Myers CW. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome. DICP. 1991;25(11):1259–62. https://doi.org/10.1177%2F106002809102501116; CSM/MCA. L-Tryptophan (Optimax): limited availability for resistant depression. Current Problems in Pharmacovigilance. 1994;20:2.; Kaufman LD, Gruber BL, Gregersen PK. Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet. 1991;337(8749):1071–4. https://doi.org/10.1016/0140-6736(91)91717-9; Swygert LA, Maes EF, Sewell LE, Miller L, Falk H, Kilbourne EM. Eosinophilia-myalgia syndrome: results of national surveillance. JAMA. 1990;264(13):1698–703. https://doi.org/10.1001/jama.1990.03450130070029; Weber RW. Adverse drug effects and the spectrum of eosinophilic pulmonary disorders. Ann Allergy Asthma Immunol. 1995;74(6):451–3.; Salzman MB, Valderrama E, Sood SK. Carbamazepine and fatal eosinophilic myocarditis. N Engl J Med. 1997;336(12):878–9. https://doi.org/10.1056/NEJM199703203361216; Mahatma M, Haponik EF, Nelson S, Lopez A, Summer WR. Phenytoin-induced acute respiratory failure with pulmonary eosinophilia. Am J Med. 1989;87(1):93–4. https://doi.org/10.1016/S0002-9343(89)80490-5; Lazoglu AH, Boglioli LR, Dorsett B, Macris NT. Phenytoin-related immunodeficiency associated with Loеffler’s syndrome. Ann Allergy Asthma Immunol. 1995;74(6):479–82.; Kaufman J, O’Shaughnessy I. Eosinophilic pleural effusion associated with valproic acid administration. South Med J. 1995;88(8):881–2. http://dx.doi.org/10.1097/00007611-199508000-00023; Rich MW, Thomas RA. A case of eosinophilic pneumonia and vasculitis induced by diflunisal. Chest. 1997;111(6):1767–9. https://doi.org/10.1378/chest.111.6.1767; Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia: review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med. 1992;152(7):1521–4. https://doi.org/10.1001/archinte.1992.00400190139026; Khalil H, Molinary E, Stoller JK. Diclofenac (Voltaren)-induced eosinophilic pneumonitis: case report and review of the literature. Arch Intern Med. 1993;153(14):1649–52. https://doi.org/10.1001/archinte.1993.00410140031004; Quinn JP, Weinstein RA, Caplan LR. Eosinophilic meningitis and ibuprofen therapy. Neurology. 1984;34(1):108. https://doi.org/10.1212/WNL.34.1.108; Edelman J, Mastaglia GL, Owen ET. The clinical significance of eosinophilia during gold salt therapy in rheumatoid arthritis. Aust N Z J Med.1981;11:723.; Cooke N, Bamji A. Gold lung. Rheumatology. 1981;20(3):129–35. https://doi.org/10.1093/rheumatology/20.3.129; Andreu V, Bataller R, Caballería J, Rodés J. Acute eosinophilic pneumonia associated with ranitidine. J Clin Gastroenterol. 1996;23(2):160–2.https://doi.org/10.1097/00004836-199609000-00023; Gafter U, Komlos L, Weinstein T, Zevin D, Levi J. Thrombocytopenia, eosinophilia, and ranitidine. Ann Intern Med. 1987;106(3):477. https://doi.org/10.7326/0003-4819-106-3-477_1; Tishler M, Abramov AL. Cimetidine-induced eosinophilia. Drug Intell Clin Pharm. 1985;19(5):377–8. https://doi.org/10.1177%2F106002808501900510; Smith JD, Chang KL, Gums JG. Possible lansoprazole-induced eosinophilic syndrome. Ann Pharmacother. 1998;32(2):196–200. https://doi.org/10.1345/aph.17190; D’adamo G, Spinelli C, Forte F, Gangeri F. Omeprazole-induced acute interstitial nephritis. Ren Fail. 1997;19(1):171–5. https://doi.org/10.3109/08860229709026272; Timmer R, Duurkens VA, Van Hees PA. Sulphasalazine-induced eosinophilic pneumonia. Neth J Med. 1992;41(3–4):153–7.; Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol. 1996;91(5):1039–40.; Bell RJM. Pulmonary infiltration with eosinophils caused by chlorpropamide. Lancet. 1964;283(7345):1249–50. https://doi.org/10.1016/S0140-6736(64)91872-0; Diffee JJ 3rd, Hayes JM, Montesi SA, Greene WL, Milnor PJr. Chlorpropamide-induced pulmonary infiltration and eosinophilia with multisystem toxicity. J Tenn Med Assoc. 1986;79(2):82–4.; Parker PH, GhishanFK, Shanks D, Greene HL. Eosinophilia associated with cholestyramine. Clin Pediatr (Phila). 1981;20(10):675–6.; Weller PF. Eosinophilia and eosinophil-related disorders. In: Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FE, eds. Middleton's Allergy: Principles and Practice. 6th ed. Philadelphia: Mosby; 2003. Р. 1105–26.; Falchi L, Verstovsek S. Eosinophilia in hematologic disorders. Immunol Allergy Clin North Am. 2015;35(3):439–52. https://doi.org/10.1016/j.iac.2015.04.004; Teragaki M, Kawano H, Makino R, Inoue K, Sai Y, Hosono M, et al. A case of warfarin-induced eosinophilia. Intern Med. 2012;51(12):1627–9. https://doi.org/10.2169/internalmedicine.51.7138; Pfitzenmeyer P, Meier M, Zuck P, Peiffer G, Masson P, Turcu A, et al. Piroxicam induced pulmonary infiltrates and eosinophilia. J Rheumatol. 1994;21(8):1573–7.; Bando T, Fujimura M, Noda Y, Hirose J, Ohta G, Matsuda T. Minocycline-induced pneumonitis with bilateral hilar lymphadenopathy and pleural effusion. Intern Med. 1994;33(3):177–9. https://doi.org/10.2169/internalmedicine.33.177; Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. Arch Intern Med. 1992;152(9):1913–9. https://doi.org/10.1001/archinte.1992.00400210133023; Bain GA, Flower CD. Pulmonary eosinophilia. Eur J Radiol. 1996;23(1):3–8. https://doi.org/10.1016/0720-048X(96)01029-7; Martin DM, Goldman JA, Gilliam J, Nasrallah SM. Gold-induced eosinophilic enterocolitis: response to oral cromolyn sodium. Gastroenterology. 1981;80(6):1567–70. https://doi.org/10.1016/0016-5085(81)90274-2; https://www.risksafety.ru/jour/article/view/156

Διαθεσιμότητα: https://www.risksafety.ru/jour/article/view/156
https://doi.org/10.30895/2312-7821-2019-7-4-176-189

ОБОСНОВАНИЕ КОМБИНИРОВАННЫХ МЕТОДОВ ЛЕЧЕНИЯ ЭПИЛЕПСИИ

Συγγραφείς: Лапоногов, О., Костюк, К., Медведев, Ю., Лебедь, В., Канайкин, А., Федосенко, Т., Гнедкова, И.

Θεματικοί όροι: ЭПИЛЕПСИЯ, СУДОРОЖНЫЕ ПРИПАДКИ, ПСИХИЧЕСКИЕ РАССТРОЙСТВА, СТЕРЕОТАКСИЧЕСКИЕ ОПЕРАЦИИ, ПРОТИВОСУДОРОЖНЫЕ ПРЕПАРАТЫ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/obosnovanie-kombinirovannyh-metodov-lecheniya-epilepsii
http://cyberleninka.ru/article_covers/15028493.png

Обоснование комбинированных методов лечения эпилепсии

Πηγή: Український нейрохірургічний журнал.

Θεματικοί όροι: 3. Good health, ЭПИЛЕПСИЯ, СУДОРОЖНЫЕ ПРИПАДКИ, ПСИХИЧЕСКИЕ РАССТРОЙСТВА, СТЕРЕОТАКСИЧЕСКИЕ ОПЕРАЦИИ, ПРОТИВОСУДОРОЖНЫЕ ПРЕПАРАТЫ

Περιγραφή αρχείου: text/html

Σύνδεσμος πρόσβασης: http://cyberleninka.ru/article/n/obosnovanie-kombinirovannyh-metodov-lecheniya-epilepsii
http://cyberleninka.ru/article_covers/15028493.png

Протисудомна й антидепресивна активність нових комплексів SnCl4 з саліцилоїлгідразонами бензальдегіду та 4-бромбензальдегіду при пероральному введенні ; Anticonvulsant and antidepressant activity of new complexes of sncl4 with salicyloylhydrazones of benzaldehyde and 4-brombenzaldehyde by oral administration

Συγγραφείς: Александрова, О. І., Кравченко, І. А., Прокопчук, О. Г., Шматкова, Н. В., Сейфулліна, І. Й., Alexandrovа, О. I., Kravchenko, I. A., Prokopchuk, О. G., Shmatkova, N. V., Seyfullina, І. Y.

Θεματικοί όροι: соединения на основе хлорида олова (IV) с салицилоилгидразонами бензальдегида и 4-бромбензальдегида, противосудорожные препараты, антидепрессивные препараты, создание новых фармацевтических препаратов, antidepressant and anticonvulsant activity, new complex compounds based on tin chloride (IV) with salicyloylhydrazones benzaldehyde and 4-brombenzaldehyde

Περιγραφή αρχείου: application/pdf

Relation: http://repo.odmu.edu.ua:80/xmlui/handle/123456789/2266

Διαθεσιμότητα: http://repo.odmu.edu.ua:80/xmlui/handle/123456789/2266

Популяционный фармакокинетический анализ данных терапевтического лекарственного мониторинга леветирацетама у недоношенных новорожденных с неонатальными судорогами

Συγγραφείς: Бондарева И.Б., Зырянов С.К., Ивжиц М.А.

Πηγή: Pediatriya - Zhurnal im G.N. Speranskogo

Θεματικοί όροι: premature infants, neonatal seizures, anti-seizure drug, levetiracetam, therapeutic drug monitoring, population modeling, pharmacokinetics, недоношенные новорожденные, неонатальные судороги, противосудорожные препараты, леветирацетам, терапевтический лекарственный мониторинг, популяционное моделирование, фармакокинетика

Relation: https://repository.rudn.ru/records/article/record/79997/

Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/79997/

Влияние топсавера на поведение лабораторных крыс в установке 'Приподнятый крестообразный лабиринт'

Συγγραφείς: Курицына А. П., Инюшкин А. Н.

Πηγή: Актуальные вопросы современной науки : всерос. с междунар. участием междисциплинар. науч.-практ. конф., г. Самара, 15 мая 2023 г. : сб. науч. ст. - Текст : электронный

Θέμα γεωγραφικό: противоэпилептические препараты, противосудорожные препараты, поведение животных, лабораторные крысы, топсавер, топирамат, тестовые системы, тесты

Relation: RU\НТБ СГАУ\536815

Διαθεσιμότητα: http://repo.ssau.ru/handle/Aktualnye-voprosy-sovremennoi-nauki/Vliyanie-topsavera-na-povedenie-laboratornyh-krys-v-ustanovke-Pripodnyatyi-krestoobraznyi-labirint-104119

Влияние топсавера на поведение лабораторных крыс в установке Открытое поле

Συγγραφείς: Курицына А. П., Инюшкин А. Н.

Πηγή: Актуальные вопросы современной науки : всерос. с междунар. участием междисциплинар. науч.-практ. конф., г. Самара, 15 мая 2023 г. : сб. науч. ст. - Текст : электронный

Θέμα γεωγραφικό: поведение животных, противосудорожные препараты, противоэпилептические препараты, тесты, тестовые системы, топирамат, топсавер

Relation: RU\НТБ СГАУ\536812

Διαθεσιμότητα: http://repo.ssau.ru/handle/Aktualnye-voprosy-sovremennoi-nauki/Vliyanie-topsavera-na-povedenie-laboratornyh-krys-v-ustanovke-Otkrytoe-pole-104118